ClinicalTrials.gg

Program

KGX105

A development code. Also written as “KGX105 injection”.

Its studies are led by Kangabio AUSTRALIA LTD PTY.

Furthest: phase 1, since Jul 2, 20261 company-led study, 1 open or runningNext primary completion: Sep 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kangabio AUSTRALIA LTD PTY11 open or runningphase 1since Jul 2, 2026Jul 2, 2026Sep 2028phase 1 · NCT07702955

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 2, 2026First study: phase 1 study in Advanced or Metastatic Solid TumorsFirst studyNCT07702955 · 85 planned · China

Ahead

  1. Sep 2028Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsNCT07702955

TargetBeta

CD3E →EGFR →read by rule
“KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation.”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07702955Advanced or Metastatic Solid Tumors · China1Not yet recruitingSep 202885

How it is read

Names in the registry

  • “KGX105 injection”, 1 entry

Codes read as this program: KGX105.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.